THURSDAY, Nov. 1, 2018 — Fentanyl, a powerful and dangerous synthetic opioid, is now showing up in crack cocaine and causing life-threatening overdoses. Within a recent four-day period, a Philadelphia hospital treated 18 patients for an apparent opioid overdose even though they’d only been smoking crack cocaine, researchers report. “None of them had intended to […]

by

GW Pharmaceuticals PLC (NASDAQ:GWP) announced on Thursday that Epidiolex, a cannabidiol oral medication for the treatment of seizures, is now available through a prescription in the United States. It is the first pharmaceutical formulation of a highly purified, plant-derived cannabidiol (CBD), a cannabinoid that lacks the high associated with marijuana, and is the first in […]

by

– Medication indicated for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome, two rare, severe childhood-onset epilepsies – EPIDIOLEX®, the first FDA-approved prescription pharmaceutical formulation of highly purified, plant-derived cannabidiol (CBD), a cannabinoid lacking the high associated with marijuana and the first in a new category of anti-epileptic drugs. To learn more, […]

by

– Medication indicated for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome, two rare, severe childhood-onset epilepsies – – Comprehensive support program available for eligible patients – LONDON and CARLSBAD, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), the world leader in […]

by

SciCann Therapeutics, a strategic research and development partner of Ontario-based FSD Pharma Inc., is launching a pilot clinical study in Pittsburgh to test the safety and efficacy of its proprietary “Steady Stomach” CBD combination product for treating patients with irritable bowel syndrome (IBS). Led by principal investigator Dr. Bryan Doner of Compassionate Care Certifications Centers […]

by

Delta, Kelowna, BC – October 31, 2018 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s edition of its series, Investorideas.com potcastsCM – cannabis news and stocks to watch plus insight from thought leaders and experts. Listen to the podcast: https://www.investorideas.com/Audio/Podcasts/2018/103118-StocksToWatch.mp3 Hear […]

by

TORONTO–(BUSINESS WIRE)–Oct 31, 2018–FSD Pharma Inc. (“ FSD Pharma ” or “ FSD ”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) today announced the launch of a pilot clinical study in Pittsburgh, Pennsylvania, by its strategic RD partner, SciCann Therapeutics (“ SciCann ”). The study is designed to test the safety and efficacy of SciCann’s proprietary […]

by

This press release was orginally distributed by SBWire Arvada, CO — (SBWIRE) — 10/29/2018 — Unique to industrial hemp is the high amounts of phytocannabinoids sometimes referred to as CBD which is an abbreviation for cannabidiol, a prominent naturally-occurring cannabinoid component found in cannabis sativa. Cannabidiols comprises up to 40% of the plant. CBD is […]

by

This press release was orginally distributed by SBWire Arvada, CO — (SBWIRE) — 10/29/2018 — Unique to industrial hemp is the high amounts of phytocannabinoids sometimes referred to as CBD which is an abbreviation for cannabidiol, a prominent naturally-occurring cannabinoid component found in cannabis sativa. Cannabidiols comprises up to 40% of the plant. CBD is […]

by

Medlab Clinical Ltd (ASX:MDC) has successfully completed stage I of the NanaBis™ human trial on cancer patients at Royal North Shore Hospital. NanaBis™ is one of two of Medlab’s cannabis-based medicines which contains formulations of tetrahydrocannabinol (THC) and cannabidiol (CBD). Medlab has received formal approval from the appropriate authority to proceed to stage II of […]

by

Medlab Clinical Ltd (ASX:MDC) has successfully completed stage I of the NanaBis™ human trial on cancer patients at Royal North Shore Hospital. NanaBis™ is one of two of Medlab’s cannabis-based medicines which contains formulations of tetrahydrocannabinol (THC) and cannabidiol (CBD). Medlab has received formal approval from the appropriate authority to proceed to stage II of […]

by

Fundamentals of US Regulatory Affairs, 10th Edition For 20 years, our flagship publication, Fundamentals of US Regulatory Affairs, has been giving regulatory professionals the insights and answers they need, right at their fingertips. BUY NOW … read more at: https://www.raps.org/news-and-articles/news-articles/2018/10/recon-pfizer-novartis-team-up-to-test-nash-combo

by

In his letter, “What’s Medicine got to do with it?,” Dr. March Seabrook proposes that there is no scientific basis for the use of marijuana as medicine and this, combined with the fact that the FDA has not approved its use, makes it inappropriate to ask physicians to recommend it to patients. I have researched […]

by

TORONTO, Aug. 22, 2018 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (TSX VENTURE:RVV) (OTCQB:RVVTF) (FSE:31R) (“Revive” or the “Company”), a specialty medical cannabis company, today announced that it has submitted an application to the U.S. Food and Drug Administration (“FDA”) seeking orphan drug designation of cannabidiol (“CBD”) for the treatment of hepatic ischemia and reperfusion injury […]

by